Magazine Article | April 6, 2018

Reata Pharmaceuticals: Return & Reach Beyond

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

The Enterprisers: Life Science Leadership In Action

What good can come of setback? What is the value, if any, in so-called failure? Must a “failed” clinical trial wind up in the great waste bin of misbegotten science? Actually, history answers those questions unequivocally. Setbacks can lead to new opportunities. Failure can clarify the goals, direction, and mission of the project. Trials that fail to verify the original hypothesis can light a better path to the truth. That is why merely dividing total R&D spending by successful drug approvals does not yield a real solution — one that accounts for the full value of biopharma research and development. If there were a price tag on new information or knowledge — a negative cost, so to speak — the equation would rebalance, adding value to that of new products at the macro, industry scale.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: